ZA201603903B - Orally disintegrating solid dosage unit containing an estetrol component - Google Patents

Orally disintegrating solid dosage unit containing an estetrol component

Info

Publication number
ZA201603903B
ZA201603903B ZA2016/03903A ZA201603903A ZA201603903B ZA 201603903 B ZA201603903 B ZA 201603903B ZA 2016/03903 A ZA2016/03903 A ZA 2016/03903A ZA 201603903 A ZA201603903 A ZA 201603903A ZA 201603903 B ZA201603903 B ZA 201603903B
Authority
ZA
South Africa
Prior art keywords
dosage unit
solid dosage
unit containing
orally disintegrating
disintegrating solid
Prior art date
Application number
ZA2016/03903A
Other languages
English (en)
Inventor
Johannes Jan Platteeuw
Bennink Herman Jan Tijmen Coelingh
Original Assignee
Donesta Bioscience B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201603903(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Donesta Bioscience B V filed Critical Donesta Bioscience B V
Publication of ZA201603903B publication Critical patent/ZA201603903B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2016/03903A 2013-12-12 2016-06-08 Orally disintegrating solid dosage unit containing an estetrol component ZA201603903B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196904 2013-12-12
PCT/EP2014/077127 WO2015086643A1 (en) 2013-12-12 2014-12-10 Orally disintegrating solid dosage unit containing an estetrol component

Publications (1)

Publication Number Publication Date
ZA201603903B true ZA201603903B (en) 2018-07-25

Family

ID=49759137

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/03903A ZA201603903B (en) 2013-12-12 2016-06-08 Orally disintegrating solid dosage unit containing an estetrol component

Country Status (30)

Country Link
US (2) US9884064B2 (enExample)
EP (1) EP3079671B1 (enExample)
JP (1) JP6447931B2 (enExample)
KR (1) KR102265150B1 (enExample)
CN (1) CN105979935B (enExample)
AU (1) AU2014363599B2 (enExample)
BR (1) BR112016013502B1 (enExample)
CA (1) CA2932855C (enExample)
CL (1) CL2016001411A1 (enExample)
CY (1) CY1119817T1 (enExample)
DK (1) DK3079671T3 (enExample)
EA (1) EA032306B1 (enExample)
ES (1) ES2655076T3 (enExample)
HR (1) HRP20180129T1 (enExample)
HU (1) HUE035848T2 (enExample)
IL (1) IL246082B (enExample)
LT (1) LT3079671T (enExample)
MA (1) MA39105B1 (enExample)
MX (1) MX369035B (enExample)
NO (1) NO3079671T3 (enExample)
NZ (1) NZ720906A (enExample)
PL (1) PL3079671T3 (enExample)
PT (1) PT3079671T (enExample)
RS (1) RS56738B1 (enExample)
SG (1) SG11201604741UA (enExample)
SI (1) SI3079671T1 (enExample)
SM (1) SMT201700582T1 (enExample)
TN (1) TN2016000230A1 (enExample)
WO (1) WO2015086643A1 (enExample)
ZA (1) ZA201603903B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2714712T3 (pl) 2011-06-01 2017-05-31 Estetra S.P.R.L. Metoda wytwarzania półproduktów estetrolu
MX341561B (es) 2011-06-01 2016-08-25 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE033590T2 (hu) * 2011-08-11 2017-12-28 Estetra Sprl Esztetrol alkalmazása sürgõsségi fogamzásgátlóként
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
JP6863547B2 (ja) * 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
LT3310345T (lt) * 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
US20200046729A1 (en) * 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
CA3178291A1 (en) * 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
MA51733A (fr) * 2018-02-07 2020-12-16 Estetra Sprl Composition contraceptive présentant des effets cardiovasculaires réduits
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
ES2915058B2 (es) * 2019-09-27 2024-06-21 Ind Chimica Srl Proceso para preparar (15alfa,16alfa,17beta)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol (Estetrol) e intermedios de dicho proceso
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CN113552768B (zh) 2020-04-24 2025-06-17 爱天思株式会社 感光性着色组合物、彩色滤光片及图像显示装置
CA3194494A1 (en) 2020-09-29 2022-04-07 Millicent Pharma Limited Orodispersible formulations
DE112023005720T5 (de) 2023-02-02 2025-12-11 Industriale Chimica S.R.L VERFAHREN ZUR HERSTELLUNG VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRAT
WO2025181200A1 (en) 2024-02-28 2025-09-04 Estetra Srl Estetrol polymorphic form and production thereof
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DE60217324T2 (de) * 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
ES2337129T3 (es) * 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
RS50909B (sr) * 2002-02-21 2010-08-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutske kompozicije koje se sastoje od jednog ili više steroida, jedne ili više tetrahidrofolatne komponente i vitamina b12
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
SG174785A1 (en) * 2006-06-08 2011-10-28 Warner Chilcott Co Llc Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
AU2007325207A1 (en) * 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
JP5649305B2 (ja) * 2006-12-20 2015-01-07 テバ ウィメンズ ヘルス インコーポレイテッド プロゲスチンを含む口腔内崩壊性固体剤形ならびにその製造方法および使用方法
WO2008089087A2 (en) * 2007-01-12 2008-07-24 Wyeth Tablet-in-tablet compositions
ATE537833T1 (de) * 2007-06-21 2012-01-15 Pantarhei Bioscience Bv Behandlung des mekoniumaspirationssyndroms mit östrogenen
WO2010033832A2 (en) 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
DE102009007771B4 (de) * 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102058604A (zh) * 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens

Also Published As

Publication number Publication date
US9884064B2 (en) 2018-02-06
EA201691226A1 (ru) 2016-10-31
CL2016001411A1 (es) 2016-11-11
HRP20180129T1 (hr) 2018-02-23
RS56738B1 (sr) 2018-03-30
KR102265150B1 (ko) 2021-06-16
CY1119817T1 (el) 2018-06-27
LT3079671T (lt) 2018-02-12
CN105979935A (zh) 2016-09-28
KR20160102212A (ko) 2016-08-29
WO2015086643A1 (en) 2015-06-18
JP2016540021A (ja) 2016-12-22
AU2014363599B2 (en) 2019-10-31
US20180117063A1 (en) 2018-05-03
EA032306B1 (ru) 2019-05-31
IL246082B (en) 2018-03-29
MA39105A1 (fr) 2017-04-28
BR112016013502A2 (pt) 2018-07-03
JP6447931B2 (ja) 2019-01-09
BR112016013502B1 (pt) 2021-05-11
EP3079671A1 (en) 2016-10-19
HUE035848T2 (en) 2018-05-28
DK3079671T3 (en) 2017-12-11
EP3079671B1 (en) 2017-10-25
TN2016000230A1 (en) 2017-10-06
SI3079671T1 (en) 2018-04-30
PT3079671T (pt) 2017-11-24
CA2932855C (en) 2022-07-19
MX2016007595A (es) 2016-11-28
ES2655076T3 (es) 2018-02-16
SG11201604741UA (en) 2016-07-28
NO3079671T3 (enExample) 2018-03-24
US20160310506A1 (en) 2016-10-27
IL246082A0 (en) 2016-07-31
CA2932855A1 (en) 2015-06-18
US9987287B2 (en) 2018-06-05
NZ720906A (en) 2022-04-29
MA39105B1 (fr) 2018-05-31
MX369035B (es) 2019-10-25
AU2014363599A1 (en) 2016-06-30
SMT201700582T1 (it) 2018-03-08
CN105979935B (zh) 2019-07-26
PL3079671T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
ZA201603903B (en) Orally disintegrating solid dosage unit containing an estetrol component
ZA201601604B (en) Comminuting device
ZA201604451B (en) Immediate release abuse-deterrent granulated dosage forms
SG10201708409VA (en) Medicament device
PL2857103T3 (pl) Urządzenie rozdrabniające
IL245125B (en) Immediate-release granulated dosage forms prevent abuse
PL3044840T3 (pl) Urządzenie rozładowujące
IL243242B (en) Stable pharmaceutical dosage forms containing atresantan
IL245705A0 (en) Pharmaceutical dosage forms
IL241350A0 (en) Subprevir tablets
IL241580B (en) Solid dosage forms for delayed release of antiemetic agents
ZA201603463B (en) An inhalable medicament
IL245760A0 (en) Inhalation medicine
GB201305103D0 (en) An oral dosage form
GB201413253D0 (en) Solid dosage form
AU355916S (en) Telescopic chute
GB201404271D0 (en) Superforwarding processor
PH32013000879S1 (en) Cabinet (conseca commode)
GB201320786D0 (en) Medicament
GB201314860D0 (en) Processor
GB201316662D0 (en) Pharmaceutical Combination